The third-quarter 2026 reporting cycle for the Medical sector is in full swing, with most companies having already reported their results and several others scheduled to release this week. The earnings season for the drug and biotech sector kicked off around mid-October when pharma bellwether Johnson & Johnson reported third-quarter results. While it beat earnings estimates, sales fell slightly short. J&J consequently raised its sales expectations for 2026 to reflect a strong operational performance so far this year. Last week, Merck reported strong third-quarter results, beating estimates for both earnings and sales as Keytruda and newer products continued to drive growth. The company also raised its 2026 earnings outlook.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.